Article Text

PDF
Heart failure and cardiomyopathy
Pathological role of angiostatin in heart failure: an endogenous inhibitor of mesenchymal stem-cell activation
  1. K Yamahara1,
  2. K D Min2,
  3. H Tomoike2,
  4. K Kangawa3,
  5. S Kitamura4,
  6. N Nagaya1
  1. 1
    Department of Regenerative Medicine & Tissue Engineering, National Cardiovascular Center Research Institute, Osaka, Japan
  2. 2
    Department of Cardiovascular Medicine, National Cardiovascular Center, Osaka, Japan
  3. 3
    Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka, Japan
  4. 4
    Department of Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan
  1. Dr K Yamahara, Fujishirodai 5-7-1, Suita, Osaka 565-8565, Japan; yamahara{at}ri.ncvc.go.jp

Abstract

Objective: Recently, a clinical trial was initiated to evaluate the efficacy of transendocardial transplantation of autologous bone marrow-derived mesenchymal stem cells (MSC) for the treatment of heart failure (HF). Because some HF patient-derived sera did not induce proliferation of autologous MSC, the present study aimed to elucidate humoral factors in sera that attenuate MSC activation and to investigate the role of these humoral factors in the pathogenesis of HF.

Methods and results: Inhibitory effects present in serum were analysed by culturing human MSC with sera from 10 HF patients (FS <25%, BNP >100 pg/ml) and four healthy control subjects. Among the patients, two sera from HF patients showed significant inhibitory activity on MSC proliferation. Protein array and ELISA analysis revealed that these sera contained high levels of angiostatin as well as the active form of matrix metalloproteinase (MMP)-9, which generates angiostatin. Angiostatin significantly inhibited the proliferation and migration of cultured human MSC and increased their apoptosis in a dose-dependent manner. In a rat HF model, serum levels of angiostatin and MMPs increased, but treatment with an MMP inhibitor suppressed these increases.

Conclusions: The results suggest that angiostatin, which can attenuate the activity of MSC, might play a role in the progression of HF.

Statistics from Altmetric.com

Footnotes

  • See Editorial, p 269

  • ▸ Additional tables are published online only at http://heart.bmj.com/content/vol95/ issue4

  • Funding: This work was supported by a grant-in-aid for scientific research (the Japanese Ministry of Education, Culture, Sports, Science and Technology) and a research grant for cardiovascular disease (the Japanese Ministry of Health, Labour and Welfare).

  • Competing interests: None.

  • Ethics approval: Ethics approval was provided by the Ethics Committee of the National Cardiovascular Centre, Osaka, Japan.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles